RE: seeks input on Study Data Exchange Standards

One of my PhD thesis work was to automatically convert HL7 Version 2 and
Version 3 into ontological formats (i.e., OWL ontologies). In a way, my
work was an attempt to create a set of value propositions for "an
ontology-based integration framework" in resolving the heterogeneities
of healthcare applications (particularly HL7). Outcome of the thesis was
www.ppepr.com system, where we have shown the benefits (as well as
limitations) of using the "semantics" in HL7 environment. For people who
are involved in similar efforts, this can also be an opportunity to
establish the common ground for "HL7 + Semantic Web" system. Though
ambitious, one idea would be create a SW profile for HL7 (other than XML
and UML based ITS), very similar to OWL profiles
http://www.w3.org/TR/owl2-profiles/ targeting specialised application
scenarios.  

Please let me know if anything I can add to this effort.


Regards,

Dr. Ratnesh Sahay
Research Associate
Health Care and Life Sciences (HCLS)
Digital Enterprise Research Institute (DERI),
National University of Ireland, IDA Business Park,
Lower Dagan, Galway, Ireland
Ph (office): + 35391495253
Fax (office): + 35391495541
WWW: http://www.deri.ie/about/team/member/ratnesh_sahay/   


-----Original Message-----
From: Mead, Charlie (NIH/NCI) [C] [mailto:meadch@mail.nih.gov] 
Sent: 15 August 2012 07:02
To: Kerstin Forsberg; HCLS hcls
Subject: RE: seeks input on Study Data Exchange Standards

I would say Yes -- particularly since there is now an effort to
represent some of newest HL7 standards -- FHIR resource definitions in
particular -- using SW approaches...and the BRIDG OWL representation
will almost certainly benefit from this effort.

charlie
________________________________________
From: Kerstin Forsberg [kerstin.l.forsberg@gmail.com]
Sent: Wednesday, August 15, 2012 1:57 AM
To: HCLS hcls
Subject: FDA: seeks input on Study Data Exchange Standards

FDA seeks "input from industry, technology vendors, and other members of
the public regarding the advantages and disadvantages of current and
emerging open, consensus-based standards for the exchange of regulated
study data. "

In the annoncement for a meeting 5 November FDA ask for responses,
before 5 October, on questions such as "- What are the advantages and
disadvantages of HL7 v3 and CDISC ODM?"

And, interestingly, they also ask: "- Are there other open data exchange
standards that should be evaluated?"

Is this an opportunity for a semantic web based proposal?

Kind Regards

Kerstin Forsberg

AstraZeneca



https://www.federalregister.gov/articles/2012/08/14/2012-19748/regulator
y-new-drug-review-solutions-for-study-data-exchange-standards-notice-of-
meeting-request-for

Received on Wednesday, 15 August 2012 13:37:16 UTC